Docetaxel added to androgen deprivation therapy (ADT) was the most cost-effective first-line regimen for patients with ...
Germline testing can identify hereditary cancer, which leads to implications for family members, cascade testing for relatives, and starting surveillance and prevention measures: Genetic testing in ...
Identification of variants influences treatment decisions. Inhibitors of the poly-ADP-ribose polymerase (PARP) system, a pathway for repairing single-stranded DNA breaks, are recommended for tumors ...
Lymphocyte Infiltration Score and Spatial Characteristics Refined the Prognosis and Denosumab Treatment Responsiveness Indicators for Giant Cell Tumor of Bone Outcomes data for DNA-damaging ...
The 2026 European Association of Urology (EAU) annual meeting featured a PARP inhibitors for prostate cancer session and a presentation by Dr. Martin Gleave discussing how to optimize tissue biopsy ...
A phase 1b/2 study evaluating the activity of tinengotinib in combination with androgen receptor pathway inhibitors (ARPIs) in patients with metastatic castration resistant prostate cancer (mCRPC). A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results